MicroRNA-328-3p (miR-328-3p)

MicroRNA-328-3p is a small non-coding RNA molecule that serves as a pivotal post-transcriptional regulator of gene expression across various tissues (miRBase, 2023). It exerts its biological effects by binding to the 3' untranslated regions (UTRs) of target messenger RNAs, leading to either translational inhibition or mRNA degradation (PubMed, PMID: 20530001). One of its most well-documented roles is in the heart, where it regulates the expression of L-type calcium channel subunits (CACNA1C and CACNB2), and its upregulation is a known driver of electrical remodeling in atrial fibrillation (Circulation, 2010). Beyond cardiovascular health, miR-328-3p is significantly involved in cancer progression, where it can act as a tumor suppressor by regulating the breast cancer resistance protein (ABCG2) and influencing drug sensitivity (Molecular Pharmacology, 2009). It also plays a role in pulmonary hypertension by modulating pulmonary artery smooth muscle cell proliferation (PubMed, PMID: 24503114). Therapeutic interventions currently focus on using antagomirs, such as MGN-4220, to inhibit its activity in cardiac disease or synthetic mimics to restore its function in oncology (Nature Reviews Drug Discovery, 2017). Despite its potential, the primary challenges in targeting miR-328-3p involve achieving precise delivery to target tissues and managing the broad off-target effects inherent to microRNA-based therapies (NIH, 2021).

Other names

hsa-miR-328-3pmiR-328MicroRNA 328MIR328

MicroRNA-328-3p functions by binding to the 3' untranslated region (UTR) of target messenger RNAs (mRNAs), which leads to translational repression or mRNA degradation through the RNA-induced silencing complex (RISC) (PubMed, PMID: 20530001).